<DOC>
	<DOC>NCT01183598</DOC>
	<brief_summary>This open-label, single center study will provide RoActemra/Actemra (tocilizumab) to a maximum of 4 patients with Multicentric Castelman's Disease who have demonstrated benefit from RoActemra/Actemra in study MRA004US (Chugai Pharma USA) without major toxicities or significant adverse events. Patients will receive their most effective maintenance dose until disease progression or significant toxicity occurs.</brief_summary>
	<brief_title>A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment</brief_title>
	<detailed_description />
	<mesh_term>Giant Lymph Node Hyperplasia</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Evidence of improvement of one or more clinical benefit criteria with acceptable tolerability to RoActemra/Actemra in Protocol MRA001US, maintained clinical benefit in MRA004US, and completion of MRA004US Life expectancy &gt; 12 weeks Zubrod performance status &lt;/= 3 Serious toxicity including anaphylactic reactions to tocilizumab during the MRA004US trial Any treatment for Multicentric Castleman's Disease except for corticosteroids within 2 weeks prior to Day 1 Active infection requiring iv antibiotics for &gt; 1 month and not resolving at least 1 week prior to Day 1; iv antibiotics prophylaxis for infections of implanted venous access portals is allowed Active viral infection within 28 days prior to Day 1 Treatment with any investigational agent other than RoActemra/Actemra within 30 days prior to baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>